Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Rangering i aksjer #3998
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aksjekurs
$32.53
Markedsverdi
$4.09B
Endring (1 dag)
1.99%
Endring (1 år)
55.77%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)

Kategori

Healthcare
Antall utestående aksjer for Arcutis Biotherapeutics, Inc. (ARQT)
Antall utestående aksjer per June 2026: 130.52M
Ifølge Arcutis Biotherapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 130.52M. Ved slutten av December 2023 hadde selskapet 69.31M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Arcutis Biotherapeutics, Inc. (ARQT) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 130.52M 7.91%
2024 120.96M 74.53%
2023 69.31M 25.94%
2022 55.03M 11.39%
2021 49.41M 38.52%
2020 35.67M -6.36%
2019 38.09M 5.11%
2018 36.24M 3,331.44%
2017 1.06M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 94.53%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 203.40%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 266.92%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -52.36%
NL